跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 90,113 条关于
“505(b)(2) medicines”
全部
90,113
临床试验
55,597
药物
10,604
机构
4,169
资讯
19,743
6个月前
Arna Pharma and Slate Run Pharmaceuticals Form Joint Venture to Create Scaled U.S. Specialty Pharmaceutical Platform
去年
FDA Approves Multiple ANDAs and 505(b)(2) Applications in Q3
去年
LadRx Plans NDA Submission for Aldoxorubicin Under 505(b)(2) Pathway
3年前
FDA Accepts Satsuma Pharmaceuticals' NDA for STS101 Migraine Treatment
去年
CMS Policy Changes Create New Reimbursement Challenges for 505(b)(2) Oncology Drugs
去年
Zydus Lifesciences Secures Two Strategic Partnerships for Novel 505(b)(2) Oncology Products in US Market
去年
Strategic Patent Extensions and 505(b)(2) Applications: Key Pathways for Post-ANDA Market Exclusivity
上个月
FDA Issues Draft Guidance Clarifying When to Submit an ANDA Versus a 505(b)(2) Application
去年
Indian Pharma Companies Leverage FDA 505(b)(2) Pathway to Create Differentiated Generics with Merck Support
10个月前
FDA 505(b)(2) Pathway Drives 69 Drug Reformulations in 2024-2025, Focusing on Stability and Patient Experience
第 1 页,共 1975 页
上一页
下一页